ClinicalTrials.gg
RecruitingNCT07794878Updated Aug 31, 2026

Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults

A Phase 3 interventional study of NOA LIFT and JUVÉDERM VOLIFT with Lidocaine in Nasolabial Folds, sponsored by AbbVie. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Nasolabial folds (NLFs) are wrinkles that run from the sides of the nose to the corners of the mouth. The goal of this study is to evaluate how safe and effective NOA LIFT is compared to JUVÉDERM VOLIFT with Lidocaine for correcting moderate to severe nasolabial folds in adults.

NOA LIFT and JUVÉDERM VOLIFT with Lidocaine are hyaluronic acid-based dermal fillers being evaluated for the treatment of nasolabial folds. Participants are randomly placed into 1 of 2 treatment groups. There is a 2 in 3 chance that participants will be assigned to the NOA LIFT group and a 1 in 3 chance of being assigned to the VOLIFT group. Around 288 adult participants with moderate to severe nasolabial folds will be enrolled at multiple sites in China.

Participants will receive deep dermis injections of either NOA LIFT or JUVÉDERM VOLIFT. The study duration is approximately 12 months after the initial treatment.

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, vital signs, laboratory tests, vision assessments, checking for side effects, and completing questionnaires.

02

Conditions studied

  • Nasolabial Folds

Keywords

  • Nasolabial Folds
  • NOA LIFT
  • JUVÉDERM VOLIFT
  • Lidocaine
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Moderate (2) or Severe (3) on the 5-point Nasolabial Fold Severity Scale (NLFSS) for each nasolabial fold (NLF) on evaluator live assessment (both sides must qualify and have the same score)

Exclusion criteria

Exclusion Criteria:

  • Current cutaneous or mucosal inflammatory or infectious processes, abscess, unhealed wound, or cancerous or precancerous lesion in the treatment area(s).
  • Current enrollment in an drug or device study or participation in such a study within 30 days before enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    NOA LIFT

    Participants will receive initial treatment with NOA LIFT injected into the nasolabial folds. Optional touch-up treatment may be administered at Day 31 if optimal aesthetic correction has not been achieved.

    Drug: NOA LIFT

  • Active comparator
    JUVÉDERM VOLIFT With Lidocaine

    Participants will receive initial treatment with JUVÉDERM VOLIFT with Lidocaine injected into the nasolabial folds. Optional touch-up treatment may be administered at Day 31 if optimal aesthetic correction has not been achieved.

    Drug: JUVÉDERM VOLIFT with Lidocaine

Interventions

  • DrugNOA LIFT

    Injection

  • DrugJUVÉDERM VOLIFT with Lidocaine

    Injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Responder Status Based on Evaluating Investigator's Live Assessment of Nasolabial Fold Severity Scale (NLFSS)

    The NLFSS is a validated 5-point scale used to assess the severity of nasolabial folds, where higher scores indicate more severe folds.

    Time frame: Month 6

  2. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 13 months

Secondary outcomes

  1. Percentage of Participants With Responder Status Based on Evaluating Investigator's Assessment of Global Aesthetic Improvement Scale (GAIS) in Nasolabial Folds (NLFs)

    A responder is defined as a participant with improvement in the GAIS in NLF (defined as improved or much improved in GAIS). The GAIS is used to assess aesthetic improvement, with higher ratings indicating greater improvement.

    Time frame: Month 6

  2. Percentage of Participants With Responder Status Based on Participant's Assessment of Global Aesthetic Improvement Scale (GAIS) in Nasolabial Folds (NLFs)

    A responder is defined as a participant with improvement in the GAIS in NLF (defined as improved or much improved in GAIS). The GAIS is used by participants to assess their own aesthetic improvement, with higher ratings indicating greater improvement.

    Time frame: Month 6

  3. Change From Baseline in the Overall Score of FACE-Q - Appraisal of Lines: Nasolabial Folds

    The FACE-Q - Appraisal of Lines: Nasolabial Folds is a patient-reported outcome measure assessing satisfaction with nasolabial fold appearance. Higher scores indicate better outcomes.

    Time frame: Up to Month 6

07

Study locations

6 of 6 sites recruiting
  • Peking Union Medical College Hospital (West) - Xidan Campus /ID# 267457
    Beijing, Beijing Municipality 100032, China
    Recruiting
  • Zhujiang Hospital /ID# 276566
    Guangzhou, Guangdong 510280, China
    Recruiting
  • Peking University Shenzhen Hospital /ID# 268255
    Shenzhen, Guangdong 518036, China
    Recruiting
  • Nanjing Drum Tower Hospital /ID# 267555
    Nanjing, Jiangsu 210008, China
    Recruiting
  • Zhongda Hospital Of Southeast University /ID# 276571
    Nanjing, Jiangsu 210009, China
    Recruiting
  • Xianyang Hospital of Yanan University /ID# 267936
    Xianyang, Shaanxi 712000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Aug 31, 2026
StartActual
Aug 19, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07794878
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Aug 19, 2026
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion